Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris

被引:146
|
作者
Chams-Davatchi, Cheyda
Esmaili, Nafiseh
Daneshpazhooh, Maryam
Valikhani, Mahin
Balighi, Kamran
Hallaji, Zahra
Barzegari, Masoumeh
Akhyani, Maryam
Ghodsi, S. Zahra
Seirafi, Hassan
Tabrizi, Mohammad-Javad Nazemi
Mortazavi, Hossein
Mirshams-Shahshahani, Mostafa
机构
[1] Univ Tehran Med Sci, Razi Hosp, Dept Dermatol, Tehran 11996, Iran
[2] Univ Tehran Med Sci, Razi Hosp, Dept Dermatol, Pemphigus Res Unit, Tehran, Iran
关键词
D O I
10.1016/j.jaad.2007.05.024
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Pemphigus is a severe autoimmune blistering disease affecting the skin and mucosa. Mortality is high in the absence of treatment. Nowadays, treatment is based mainly on corticosteroids and cytotoxic drugs; however, because of the rarity of the disease worldwide, there is not yet a standard treatment based on randomized controlled trials, and the treatment used is based mainly on the experience of experts. Objective: The aim of this study was to compare the efficacy and safety of 4 treatment regimens for pemphigus vulgaris: prednisolone alone, prednisolone plus azathioprine, prednisolone plus mycophenolate mofetil, and prednisolone plus intravenous cyclophosphamide pulse therapy. Methods: One hundred twenty new cases of pemphigus vulgaris were enrolled. These patients were randomly allocated into 1 of 4 treatment groups (each comprising 30 patients) and received prednisolone (P), prednisolone and azathioprine (P/A), prednisolone and mycophenolate mofetil (P/MM), and prednisolone and intravenous cyclophosphamide pulse therapy (P/PC). They were followed up for I year at the Pemphigus Research Unit. Results: In groups P, P/A, P/MM, and P/PC, 23 (76.5%), 24 (80%), 21 (70%), and 22 (73.3%) of the patients, respectively, followed the regimen for the full 1-year period. The mean total dose of prednisolone administered in groups P, P/A, P/MM, and P/PC was 11631 mg (standard deviation [SD] = 7742), 7712 mg (SD = 955), 9798 mg (SD = 3995), and 8276 mg (SD = 810), respectively. The mean total dose of prednisolone in group P (prednisolone alone) was 11,631 mg, The mean total dose of prednisolone in the 3 cytotoxic groups was 8652 mg. By using analysis of variance, the difference was statistically significant (P =.047). in the cytotoxic groups, there was a significant difference between the P/A and P/MM groups (P =.007), but not between P/A and P/PC (P =.971), and P/MM and P/PC (P =.670). Side effects were not significantly different among the 4 groups. Limitations: Larger sample sizes and blind design are suggested for future studies. Conclusion. The efficacy of prednisolone is enhanced when it is combined with a cytotoxic drug. The most efficacious cytotoxic drug to reduce steroid was found to be azathioprine, followed by cyclophosphamide (pulse therapy), and mycoplienolate mofetil.
引用
收藏
页码:622 / 628
页数:7
相关论文
共 50 条
  • [1] A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal
    Mariani, JJ
    Rosenthal, RN
    Tross, S
    Singh, P
    Anand, OP
    AMERICAN JOURNAL ON ADDICTIONS, 2006, 15 (01): : 76 - 84
  • [2] A Randomized Trial and the Treatment of Pemphigus Vulgaris
    Margolis, David J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2010, 130 (08) : 1964 - 1966
  • [3] Open-label Placebos for Wound Healing: A Randomized Controlled Trial
    Mathur, Ashwin
    Jarrett, Paul
    Broadbent, Elizabeth
    Petrie, Keith J.
    ANNALS OF BEHAVIORAL MEDICINE, 2018, 52 (10) : 902 - 908
  • [4] Open-Label placebo for the treatment of unipolar depression: Results from a randomized controlled trial
    Nitzan, Uri
    Carmeli, Gal
    Chalamish, Yossi
    Braw, Yoram
    Kirsch, Irving
    Shefet, Daphna
    Krieger, Israel
    Mendlovic, Shlomo
    Bloch, Yuval
    Lichtenberg, Pesach
    JOURNAL OF AFFECTIVE DISORDERS, 2020, 276 : 707 - 710
  • [5] Open-label placebo treatment in chronic low back pain: a randomized controlled trial
    Carvalho, Claudia
    Caetano, Joaquim Machado
    Cunha, Lidia
    Rebouta, Paula
    Kaptchuk, Ted J.
    Kirsch, Irving
    PAIN, 2016, 157 (12) : 2766 - 2772
  • [6] Role of doxycycline in the treatment of dengue infection: An open-label, randomized, controlled, pilot trial
    Kumar, Banothu Vinod
    Kamboj, Kajal
    Pannu, Ashok Kumar
    Yadav, Ashok Kumar
    Bhatia, Mandip
    Saroch, Atul
    ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE, 2024, 17 (04) : 160 - 165
  • [7] Open-Label placebo for the treatment of unipolar depression: Results from a randomized controlled trial
    Nitzan, U.
    EUROPEAN PSYCHIATRY, 2023, 66 : S845 - S846
  • [8] Open-Label placebo for the treatment of unipolar depression: Results from a randomized controlled trial
    Nitzan, U.
    EUROPEAN PSYCHIATRY, 2023, 66 : S845 - S846
  • [9] An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy
    Sharma, Praveen
    Sharma, Barjesh C.
    Puri, Vinod
    Sarin, Shiv Kumar
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2008, 20 (06) : 506 - 511
  • [10] Phenobarbitone versus phenytoin for treatment of neonatal seizures: An open-label randomized controlled trial
    Pathak G.
    Upadhyay A.
    Pathak U.
    Chawla D.
    Goel S.P.
    Indian Pediatrics, 2013, 50 (8) : 753 - 757